Tezspire
Chemical Name | tezepelumab-ekko |
Dosage Form | Injection (subcutaneous; 210 mg/1.91 mL (110 mg/mL)) |
Drug Class | Monoclonal antibodies |
System | Respiratory |
Company | Amgen |
Approval Year | 2021 |
Indication
- For the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma